How GOJO Could Shape Clorox's Fiscal 2027 Growth and Margin Outlook
Clorox (CLX) expects fiscal 2027 net sales to rise 13-14%, with GOJO contributing 9.5 points. Q1 sales projected at 31-32%, including 15 points from GOJO. Adjusted earnings forecasted at $5.70-$6.00 per share, up 3-8%. Gross margin expected at 42%, with pressure from GOJO inventory costs and inflation. Integration costs and inflation pose near-term challenges.
How this was made
The 30-second read
Why it matters
The FY2027 guidance reflects both organic growth and the acquisition's contribution, offering a new valuation baseline.
Market read
New FY2027 guidance for CLX, driven by the GOJO deal, provides fresh material for investors and may shift sector sentiment.
What to watch
Potential inventory step‑up costs and inflationary pressures may erode the projected earnings accretion.
Background
Clorox completed its acquisition of GOJO in April 2026, creating a combined health‑and‑hygiene platform.
Ticker impact
Clorox disclosed FY2027 net sales guidance of +13‑14% and adjusted EPS $5.70‑$6.00, driven by the GOJO acquisition.
Potential modest upside as investors price in higher sales and earnings.
Guidance is new, material, and reflects a sizable acquisition contribution.
Market effects
Strengthens the consumer staples sector outlook by showing successful hygiene‑product consolidation.
U.S. consumer‑goods investors may re‑price exposure to health‑and‑hygiene brands.
Highlights the trend of large consumer firms acquiring niche hygiene players worldwide.
Counterpoint
Integration costs and margin pressure could offset sales boost, leading to a muted reaction.
Key entities
- CompanyThe Clorox Company
Consumer staples firm (ticker CLX) reporting FY2027 guidance.
- CompanyGOJO Industries
Hygiene products maker (ticker GOJO) now part of Clorox.
